Now accepting APC Fellow applications
It may seem early, but now is the time to get started on your application for the APC Fellows Program.
It may seem early, but now is the time to get started on your application for the APC Fellows Program.
This week, APC submitted letters to two state legislatures—a joint letter with NCPA to Hawaii and a letter to Mississippi.
If you own or manage a compounding pharmacy, here are 10 questions to think about.
FDA recently released this year’s CDER Guidance Agenda, a list of new, revised draft, and immediately-in-effect guidance documents it plans to publish this year. There are five listed in the compounding category.
Pharmacist Tenille Davis officially started in her new role as APC’s chief advocacy officer yesterday.
APC submitted comments this week to the Illinois Board of Pharmacy regarding its proposed rule on nonresident pharmacies.
FDA has added a new section to its Q&A webpage for GFI #256 - Compounding Animal Drugs from Bulk Drug Substances. Here are the high points.
In life, we might not get what we wish for, but we will definitely get what we work for.
Dr. Pam Smith and the University of South Florida Health Morsani College of Medicine just launched a program designed for pharmacists and focused on a practical approach to BHRT and functional medicine.
We’re doing something new for this year’s Owner Summit: Sign up by February 15 and we’ll knock $300 off your registration cost.
This coming week will be like musical chairs at APC, except there’ll be seats enough for us all.
If you haven’t joined APC’s group purchasing deal with Worldpay, you might be throwing away money.
APC has submitted responses to an environmental scan request from FDA’s Center for Veterinary Medicine (CVM). This feedback is intended to provide perspective and allow the agency to address weaknesses.
In a significant ruling this week, a U.S. district judge granted SCA's request and issued a sealed temporary restraining order to block FDA from publishing unsupported concerns about the sterility of the 503B facility.
This year, we have 36 Corporate Patrons signed on in support of APC, including 22 Tier Corporate Patrons.
The professional development event of the year for compounding pharmacy and facility owners and managers is back, and it’s better than ever.
It was another week of interesting reporting on GLP-1s—compounded, counterfeit, and commercially available. APC continues to field multiple media inquiries each week about the GLP-1 craze and compounding’s role in shortages.
We’ve got some new tools to help you educate and inform prescribers about the threat to compounded hormone therapy.
APC submitted comments this week on FDA’s Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act.
In a listening session with representatives from FDA’s Center for Drug Evaluation & Research this week, APC leaders again pressed FDA to support a proposal to eliminate the MOU on interstate shipments of compounded medications.
This week, just two weeks into the new year, in a special-called APC Board of Directors meeting, I resigned as your 2024 APC Board Chair effective January 31. On February 1, I will join the APC staff as Chief Advocacy Officer.
Pharmacies across the country have been flooded with the fax pictured below. Thing is, it’s a scam.
On December 5, APC submitted comments to the Senate Finance Committee for a hearing on drug shortages.
The Pharmacy Compounding Foundation has awarded $1,500 compounding education grants to eight state pharmacy associations for 2024.
APC’s fourth annual Owner Summit April 4-6 in LaJolla, Calif., will include a session called “Don’t Bother: Things Not to Try.”
Happy new year! Thanks to what we achieved in 2023 — especially our membership revenue growth — we’re well positioned to do even more in 2024.
As we prepare to celebrate the end of one year and the beginning of another, it seems like a natural time for us all to reflect on what we accomplished in 2023.
Christmas has come early for pharmacy owner Jack Korbutov.
Revelation Pharma and Empower have joined Medisca as Diamond-level corporate patrons for 2024.
We’ve got some new tools especially designed to help you educate and inform prescribers about the threat to compounded hormone therapy.